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matol 1987; 17:469–472.HIV prevention and treatment research in sub-Saharan Africa: where are the adolescents?Some two decades into the, predominantly heterosexual,
HIV epidemic in sub-Saharan Africa, we have yet to
challenge the epidemic in a concerted fashion in perhaps
its most pertinent population. Not only has little
intervention research been carried out on adolescents
in sub-Saharan Africa but also the trials that have involved
this group do not seem to have been given due attention.
The continued spread of new HIV infections and rapidly
increasing morbidity and mortality characterize the
maturing HIV epidemic in sub-Saharan Africa. The
latest AIDS epidemic update was released in December
2005 by UNAIDS [1]. It reminds us yet again that sub-
Saharan Africa bears an increasingly disproportionate
burden of global HIV infection. Despite being home to
only one-tenth of the global population, over 60% of
all adults and children living with HIV and AIDS live in
sub-Saharan Africa; 65% of those newly acquiring HIV
(4.9 million) in 2005 were from this region, and
approximately 75% of global deaths from HIV/AIDS
(3.1 million) occurred here [1].
In 2004, 50% of new infections occurred in young adults
[2]. In contrast to the demographic profile of more
industrialized regions, in sub-Saharan Africa people
under the age of 24 years constitute the majority of the
population. More than two-fifths of the entire population
is under 15 years of age in this region [3]. It is here that we
need to aim our efforts.
Pettifor et al. [4,5] recently highlighted the central role
that young women aged 15–24 years play in fuelling the
HIV epidemic in South Africa (one of the worst affected
countries in the world). This profile of young women
bearing the brunt of the pandemic is not unique to South
Africa but a common feature of HIV infection in sub-
Saharan Africa. The infection rates in young women of
this age group are up to six times higher than in their male
counterparts in parts of sub-Saharan Africa [6]. Bio-
logical, behavioral, and socioeconomic characteristics
increase the HIV risk in youth and especially in young
women. Less than half of all young people are able to
identify correctly the major ways of preventing HIV
infection, some 20 years into the heterosexual epidemic
in this region [1].
While the rising incidence and prevalence of HIV create a
scientific and ethical imperative to undertake prevention
and treatment research in these settings, a recentCochrane analysis of HIV-related trials underway or
completed in sub-Saharan Africa by December 2004
highlights the dispiriting state of HIV-related prevention
or HIV-related treatment trials in sub-Saharan Africa [7].
The analysis examined trials that focused on prevention
or treatment of HIVor any associated factor, for example
opportunistic infections.
Siegfried et al. [7] scanned 12 815 records resulting in 284
eligible records, of which 150 referring to 77 trials were
included in their analysis. Of 67 trails whose publications
were accessible to us, we found that only 19 of the 67
trials may possibly have included adolescents, given their
enrolment criteria; none of these trials focused specifically
on young people by identifying or undertaking subgroup
analysis in this age group. Of the 30 trials involving
women’s issues (including pMTCT), five may possibly
have included adolescents.
While there is growing support for evidence-based
decision making and the randomized controlled trial as
the gold standard for evaluating new interventions, proofs
of prevention methods should be made through good-
quality research in the population that is most affected.
New treatment modalities should likewise be evaluated in
the settings where their need is greatest. In the case of
HIV infection, globally and in sub-Saharan Africa, the
epidemiological data provide a compelling basis for
prioritization of interventions targeted at adolescents and
indicate the need to include adolescents in HIV treatment
and especially prevention trials. This has yet to happen.
Our research efforts must be informed and responsive to
where the needs are greatest demographically. We must
focus urgently on prevention and treatment interventions
in young people in Africa, as well as developing a more
strategic and structured approach to reducing HIV risk in
adolescents, if we are to impact the current epidemic
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